Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/61378
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRaja Peddapyata, Prashanth-
dc.contributor.authorKumar Ega, Jagadeesh-
dc.contributor.authorSiddoju, Kavitha-
dc.date.accessioned2023-02-09T10:56:43Z-
dc.date.available2023-02-09T10:56:43Z-
dc.date.issued2023-01-
dc.identifier.issn2583-1321 (Online); 0019-5103 (Print)-
dc.identifier.urihttp://nopr.niscpr.res.in/handle/123456789/61378-
dc.description38-41en_US
dc.description.abstractThe synthesis of some new isoxazole-piperidine-1,2,3-triazoles (4a-4j) have been achieved using Sharpless Cu(I) catalyzed [3+2] cycloaddition as a key approach. The in vitro anticancer screening of all the compounds against four human cancer cell lines including MCF-7, HeLa, A549 and IMR32 has revealed that the compounds 4c and 4f exhibited promising activity against all the cell lines as compared to etoposide. Rest of the compounds have shown good to zero activity against specific cell line when compared with the positive control. Predominantly, the compound 4c is showing superior activity against IMR32 which posses IC50 value 3.2±0.3en_US
dc.language.isoenen_US
dc.publisherNIScPR-CSIR, Indiaen_US
dc.sourceIJC Vol.62(01) [Jan 2023]en_US
dc.subjectIsoindoleen_US
dc.subject1,2,3-triazoleen_US
dc.subjectAnticancer activityen_US
dc.titleSynthesis of some new isoxazole-piperidine-1,2,3-triazoles as in vitro anticancer agentsen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.56042/ijc.v62i1.70389en_US
Appears in Collections:IJC Vol.62(01) [Jan 2023]

Files in This Item:
File Description SizeFormat 
IJC_62 (2023) 38-41.pdf798.12 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.